MediciNova Announces Positive Results in NASH Mouse Model With MN-001 and Prepares to Initiate Phase 2 Trial in the U.S.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive results from a study that examined the potential clinical efficacy of MN-001 for the treatment of NASH (nonalcoholic steatohepatitis).

MN-001 administered orally once daily (10, 30, and 100 mg/kg) for 3 weeks, was evaluated in the STAM(TM) (NASH-HCC) mouse model of nonalcoholic steatohepatitis, as measured by liver biochemistry and histopathology, NAFLD activity score (NAS), and percent of fibrosis and gene expression.

Alnylam and Genzyme Form Transformational Alliance for RNAi Therapeutics as Genetic Medicines

- New Collaboration Expected to Accelerate and Expand Global Product Value for RNAi Therapeutic Genetic Medicine Pipeline, Including “Alnylam 5x15” Programs -

- Alnylam Retains Broad Product Rights in North America and Western Europe and Genzyme Obtains Rights to Access Alnylam’s Genetic Medicines Pipeline in the Rest of World and Receives Co-Development, Co-Commercialization Rights or Global Rights to 3 Programs -

- Genzyme Becomes Major Alnylam Shareholder through Purchase of $700 Million of Equity at $80/Share, Bolstering Alnylam’s Balance Sheet to Increase Investment in RNAi Therapeutics and Enabling Alnylam’s Financial Independence through to Multiple Product Launches -

Alnylam Pharmaceuticals, Inc. (ALNY), a leading RNAi therapeutics company, and Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced today that they have formed a transformational alliance for the development and commercialization of RNAi therapeutics as genetic medicines.

CorMedix Awarded European Patent for Neutrolin

CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardio-renal and infectious disease, today announced that the European Patent Office ("EPO") has granted a European patent for a low heparin catheter lock solution for maintaining patency and preventing infection in a hemodialysis catheter (sometimes referred to as "the Prosl patent"). The Company is the exclusive worldwide licensee of European Patent EP 1 814 562 B1, which was granted on January 8, 2014.

"The issuance of the Prosl patent is a significant addition to our intellectual property portfolio in the EU," said Randy Milby, CorMedix Chief Executive Officer. "This patent will strengthen our ability to compete with other catheter lock solutions and help raise the standard of catheter care Europe."

Galectin Therapeutics Announces Update on Financing Activities and Cash of $32.3 Million

Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it had sold, from October 28, 2013 through January 9, 2014, a total of 2,391,204 shares of common stock at an average price per share of $9.99 for total gross proceeds of $23,883,137 through its at-the-market (ATM) financing vehicle. The Company entered into an ATM financing arrangement with MLV & Co. LLC ("MLV") in October 2013, which provides it the opportunity to sell up to $30 million in registered shares into the open market through MLV from time-to-time under its effective shelf registration. After commissions, the Company received $23,164,712 in net proceeds. The intended use of the net proceeds is to finance the Company's planned Phase 2 program for GR-MD-02 after completion of the Phase 1 clinical trial and for general corporate purposes. The Company currently has approximately $32.3 million in cash, and there are approximately 20.7 million shares of our common stock outstanding.